Viral latency and potential eradication of HIV-1

Expert Rev Anti Infect Ther. 2012 Aug;10(8):855-7. doi: 10.1586/eri.12.68.


Although HAART can suppress plasma viral loads to undetectable levels, individuals infected with HIV-1 harbor latent reservoirs of integrated proviruses that re-emerge upon the cessation of drug treatment. The 2012 Keystone Symposium on Frontiers in HIV Pathogenesis, Therapy and Eradication highlighted the current understanding of latent infection and new methods to activate and target these reservoirs for eradication. This report focuses on a select few aspects of the discussion, including the extent that ongoing replication might contribute to the persistent viral reservoir, recent advances in activating the expression of latent proviruses, progress in developing effective animal models and potential avenues to eradicate the cells that constitute the latent reservoir.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, N.I.H., Intramural

MeSH terms

  • Animals
  • Anti-HIV Agents / pharmacology
  • Antiretroviral Therapy, Highly Active
  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / virology
  • Carrier State / drug therapy
  • Carrier State / virology
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / pathology
  • HIV Infections / virology
  • HIV-1 / immunology
  • HIV-1 / pathogenicity*
  • HIV-1 / physiology
  • Histone Deacetylase Inhibitors / pharmacology
  • Humans
  • Models, Animal
  • Proviruses / drug effects
  • Proviruses / immunology
  • Proviruses / pathogenicity
  • Treatment Outcome
  • Virus Latency*
  • Virus Replication


  • Anti-HIV Agents
  • Histone Deacetylase Inhibitors